February 11, 2026

Malignant Colossus

A closer look at cellular scale in lung adenocarcinoma cytology

The Pathologist

February 06, 2026

Baptist Health Miami Cancer Institute Names Bruna Pellini, M.D., Chief of Thoracic Medical Oncology

Board-certified thoracic oncologist Bruna Pellini, M.D., has been named chief of thoracic medical oncology at Baptist Health Miami Cancer Institute.

Baptist Health South Florida

February 04, 2026

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

KFF Health News

January 27, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Conexiant

September 03, 2025

Interventional Pulmonology at Atlantic Health, Where Precision Diagnostics Meets Patient-Centered Care

At Morristown and Overlook Medical Centers, robotic bronchoscopy and multidisciplinary collaboration are redefining what’s possible for patients with suspected lung cancer.

Atlantic Health System

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post

January 13, 2025

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.

The ASCO Post

November 24, 2024

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously...

The ASCO Post

April 21, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.

The ASCO Post